Gene Therapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Myeloma
Investigators at National Institutes of Health zero in on myeloma
August 14th, 2008
"The transcription factor IRF4 ( interferon regulatory factor 4) is required during an immune response for lymphocyte activation and the generation of immunoglobulin- secreting plasma cells(1-3). Multiple myeloma, a malignancy of plasma cells, has a complex molecular aetiology with several subgroups defined by gene expression profiling and recurrent chromosomal translocations(4,5)," scientists in the United States report. "Moreover, the malignant clone can sustain multiple oncogenic lesions, accumulating genetic damage as the disease progresses(6,7). Current therapies for myeloma can extend survival but are not curative(8,9). Hence, new therapeutic strategies are needed...
Source: Gene Therapy Weekly (2008-08-14)
|
